JOSÉ ÁNGEL
HERNÁNDEZ RIVAS
Profesor asociado de Ciencias de la Salud
Hospital Universitario Virgen de las Nieves
Granada, EspañaPublications en collaboration avec des chercheurs de Hospital Universitario Virgen de las Nieves (8)
2022
-
A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma
Blood cancer journal, Vol. 12, Núm. 4, pp. 68
-
IBRORS-MCL study: a Spanish retrospective and observational study of relapsed/refractory mantle-cell lymphoma treated with ibrutinib in routine clinical practice
International Journal of Hematology, Vol. 116, Núm. 3, pp. 381-392
-
The changing landscape of relapsed and/or refractory multiple myeloma (MM): fundamentals and controversies
Biomarker Research, Vol. 10, Núm. 1
2021
-
Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study)
Clinical Lymphoma, Myeloma and Leukemia, Vol. 21, Núm. 12, pp. e985-e999
-
The current role of the heavy/light chain assay in the diagnosis, prognosis and monitoring of multiple myeloma: An evidence-based approach
Diagnostics, Vol. 11, Núm. 11
2017
-
Use of eltrombopag for secondary immune thrombocytopenia in clinical practice
British Journal of Haematology, Vol. 178, Núm. 6, pp. 959-970
2015
-
Development and psychometric validation of a brief comprehensive health status assessment scale in older patients with hematological malignancies: The GAH Scale
Journal of Geriatric Oncology, Vol. 6, Núm. 5, pp. 353-361
2014
-
Do chronic myeloid leukemia patients with late “warning” responses benefit from “watch and wait” or switching therapy to a second generation tyrosine kinase inhibitor?
American Journal of Hematology, Vol. 89, Núm. 11, pp. E206-E211